Aggressive B-cell lymphoma with MYC/TP53 dual alterations displays distinct clinicopathobiological features and response to novel targeted agents

Manman Deng, Zijun Y. Xu-Monette, Lan V. Pham, Xudong Wang, Alexandar Tzankov, Xiaosheng Fang, Feng Zhu, Carlo Visco, Govind Bhagat, Karen Dybkaer, April Chiu, Wayne Tam, Youli Zu, Eric D. Hsi, Hua You, Jooryung Huh, Maurilio Ponzoni, Andres J.M. Ferreri, Michael B. Møller, Benjamin M. ParsonsFredrick Hagemeister, J. Han van Krieken, Miguel A. Piris, Jane N. Winter, Yong Li, Bing Xu, Phillip Liu, Ken H. Young*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Fingerprint

Dive into the research topics of 'Aggressive B-cell lymphoma with MYC/TP53 dual alterations displays distinct clinicopathobiological features and response to novel targeted agents'. Together they form a unique fingerprint.

Medicine & Life Sciences